Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer M Johnson

Showing results (81-90 of 87) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 87 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2025
Neoadjuvant nivolumab plus carboplatin and paclitaxel in patients with locally advanced resectable squamous cell carcinoma of the head and neck: a phase II, single-arm trialRalph G Zinner, Eric V Mastrolonardo, Jennifer M Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2021
Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell CarcinomaAdam J Luginbuhl, Jennifer M Johnson, Larry A Harshyne, et al.
Molecular Carcinogenesis|July 4, 2023
IL-8 correlates with nonresponse to neoadjuvant nivolumab in HPV positive HNSCC via a potential extracellular vesicle miR-146a mediated mechanismBrianna L Hill, Alyssa N Calder, Joseph P Flemming, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2025
Extracellular Matrix-MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCCPablo Llerena, Hani Samarah, Kathryn Nunes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2024
Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell CarcinomaEric V Mastrolonardo, Kathryn L Nunes, Pablo Llerena, et al.
The Lancet. Oncology|January 16, 2022
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trialJonathan D Schoenfeld, Anita Giobbie-Hurder, Srinika Ranasinghe, et al.
Cancer Cell|May 14, 2024
Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancerDaniiar Dyikanov, Aleksandr Zaitsev, Tatiana Vasileva, et al.
Pageof 9

Showing results (81-90 of 87) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 87 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2025
Neoadjuvant nivolumab plus carboplatin and paclitaxel in patients with locally advanced resectable squamous cell carcinoma of the head and neck: a phase II, single-arm trialRalph G Zinner, Eric V Mastrolonardo, Jennifer M Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2021
Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell CarcinomaAdam J Luginbuhl, Jennifer M Johnson, Larry A Harshyne, et al.
Molecular Carcinogenesis|July 4, 2023
IL-8 correlates with nonresponse to neoadjuvant nivolumab in HPV positive HNSCC via a potential extracellular vesicle miR-146a mediated mechanismBrianna L Hill, Alyssa N Calder, Joseph P Flemming, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2025
Extracellular Matrix-MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCCPablo Llerena, Hani Samarah, Kathryn Nunes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2024
Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell CarcinomaEric V Mastrolonardo, Kathryn L Nunes, Pablo Llerena, et al.
The Lancet. Oncology|January 16, 2022
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trialJonathan D Schoenfeld, Anita Giobbie-Hurder, Srinika Ranasinghe, et al.
Cancer Cell|May 14, 2024
Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancerDaniiar Dyikanov, Aleksandr Zaitsev, Tatiana Vasileva, et al.
Pageof 9